TICKERNERD
Menu
MCKMCKHealthcare · Medical Distribution

MCK Stock Forecast: McKesson Corp. Price Predictions for 2026-2027

Last close, 17 Aug 2026
$860
−1.04% on the day

The 17 Wall Street analysts covering McKesson Corp. hold a median 12-month price target of $1,000 — +16.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 17 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$101.3B
Ticker Nerd rank
86 / 100
Median analyst target
$1,000
Analysts covering
17
Total return, dividends reinvested
1W
−2.3%
1M
+2.2%
YTD
+5.0%
1Y
+28.3%
From 52W high
−13.5%
From 52W low
+28.6%
$668
$995
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MCK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores McKesson Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Value
86
Growth
84
Quality
74
Revisions
73
Issuance
71
Momentum
60
Accruals
54
Size
3

Volatility (100): The share price has been relatively steady.

Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MCK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MCK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$700$800$900$1,000$1,100Oct 25Jan 26Apr 26Jul 26MCKHigh $1,080Median $1,000Low $905

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
14 Buy3 Hold0 Sell
Low $905Median $1,000High $1,080

The green dot is the last close — the median target sits +16.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
11 Aug 2026Wells FargoMaintainsEqual-Weight$812 → $933
6 Aug 2026Evercore ISI GroupMaintainsOutperform$860 → $1,000
6 Aug 2026TD CowenMaintainsBuy$989 → $1,006
6 Aug 2026UBSMaintainsBuy$1,050 → $1,080
24 July 2026CitigroupMaintainsBuy—
24 July 2026CitigroupMaintainsBuy$945 → $1,000
21 July 2026TD CowenMaintainsBuy$1,012 → $989
21 July 2026TD CowenMaintainsBuy—
10 June 2026BarclaysMaintainsOverweight—
10 June 2026BarclaysMaintainsOverweight$1,050 → $925
14 May 2026CitigroupMaintainsBuy—
12 May 2026Wells FargoMaintainsEqual-Weight—
8 May 2026Evercore ISI GroupMaintainsOutperform—
8 May 2026JP MorganMaintainsOverweight—
8 May 2026UBSMaintainsBuy—
28 Apr 2026William BlairInitiatesOutperform—
22 Apr 2026UBSMaintainsBuy—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—
6 Apr 2026B of A SecuritiesMaintainsBuy—
18 Feb 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MCK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MCK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.8%
Analysts raising
9
Analysts cutting
1
Fundamentals

McKesson Corp. (MCK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.3×

Cheaper than 34% of US stocks

Price / sales
0.2×

Cheaper than 91% of US stocks

Price / book
−79.3×

Cheaper than 99% of US stocks

EV / EBITDA
15.7×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
7.7%

Higher than 46% of US stocks

Earnings growth (YoY)
−21.7%

Higher than 19% of US stocks

Gross margin
3.5%

Higher than 6% of US stocks

Operating margin
1.3%

Higher than 47% of US stocks

Net margin
1.1%

Higher than 50% of US stocks

Returns & dividend
Return on equity
−571.0%

Higher than 3% of US stocks

Return on assets
4.7%

Higher than 75% of US stocks

Dividend yield
0.4%

Higher than 7% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MCK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
MCKMcKesson Corp.$101.3B
86
CORCencora, Inc.$60.6B
68
CAHCardinal Health, Inc.$56.0B
96
HSICHenry Schein, Inc.$10.3B
79
HCAHCA Healthcare, Inc.*$87.7B
67
MDTMedtronic PLC*$116.2B
84
ELVElevance Health, Inc.*$86.7B
62

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own McKesson Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MCK news & analysis

Allspring Large Cap Growth Fund Q2 2026 Performance Update

Seeking Alpha · 14 Aug 2026negative

Allspring Large Cap Growth Fund underperformed the Russell 1000 Growth Index in Q2 2026. McKesson Corp. was cited among the fund's detractors for the quarter, along with KLA Corp., Advanced Micro Devices, AstraZeneca and Netflix, while Micron Technology and Snowflake were among contributors.

Why it matters — McKesson watchers would note that the company's stock weighed on a major growth fund's quarterly performance, indicating it lagged during the period.

Here's Why McKesson (MCK) is a Strong Momentum Stock

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research highlights McKesson (MCK) as a strong momentum stock, citing the Zacks Style Scores as a way to identify market-beating stocks for investment portfolios.

Why it matters — MCK watchers would note that the stock is being recognized for strong momentum characteristics by an investment research firm.

McKesson Q1 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

McKesson reported fiscal first-quarter 2027 results that exceeded its expectations, driven by broad-based momentum across its businesses. The company subsequently raised its full-year adjusted earnings outlook.

Why it matters — An earnings beat and a raised full-year outlook signal that McKesson's operating momentum is stronger than anticipated, which is a key indicator for investors tracking the company's financial trajectory.

McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)

Seeking Alpha · 8 Aug 2026positive

McKesson reported strong fiscal first-quarter results, with EPS up 20% and revenues rising 7.7%, while modestly raising its FY27 EPS guidance. The company sees GLP-1-driven momentum decelerating alongside a broader dip in its top-line growth profile, while the Wellverse spin-off and prior divestitures are streamlining the business.

Why it matters — MCK watchers would care because the company delivered solid quarterly results and raised guidance while restructuring via the Wellverse spin-off and divestitures, a development that could support a premium valuation versus peers.

McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why

Zacks Investment Research · 7 Aug 2026positive

Zacks Investment Research published an article highlighting McKesson (MCK) as an exceptional growth stock, citing its solid growth attributes and three key reasons supporting its growth potential for investors.

Why it matters — MCK watchers would care because Zacks' bullish assessment emphasizes the company's fundamental growth characteristics that could matter for future performance.

FAQ

Frequently asked questions about MCK stock

What is the MCK stock price forecast for 2026-2027?

The 17 Wall Street analysts covering McKesson Corp. have a median 12-month price target of $1,000, with estimates ranging from $905 to $1,080. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MCK stock a buy right now?

Of the 17 analysts covering McKesson Corp., 14 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks McKesson Corp. 86 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MCK?

As at 17 Aug 2026, McKesson Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will MCK stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +16.3% from the last close, and Ticker Nerd's factor model ranks McKesson Corp. 86 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MCK stock forecast for 2030?

No analyst covering McKesson Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $905 to $1,080 over the next 12 months.

How has MCK stock performed over the past year?

McKesson Corp. returned +28.3% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does McKesson Corp. do?

McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings.

What is the latest news on MCK?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Allspring Large Cap Growth Fund Q2 2026 Performance Update". Allspring Large Cap Growth Fund underperformed the Russell 1000 Growth Index in Q2 2026. McKesson Corp. was cited among the fund's detractors for the quarter, along with KLA Corp., Advanced Micro Devices, AstraZeneca and Netflix, while Micron Technology and Snowflake were among contributors.

Company

About McKesson Corp.

McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings. Its pharmaceutical distribution business supplies branded, generic, specialty, biosimilar, and over-the-counter products, while its medical-surgical operations provide clinical supplies, logistics, and equipment support. McKesson also offers technology-enabled services that help healthcare organizations manage prescriptions, practice operations, and patient care workflows. Through its broad distribution network and service platforms, McKesson plays a central role in connecting manufacturers, providers, and pharmacies across the U.S. and internationally.

CEO Mr. Brian S. Tyler Ph.D. · 41,600 employees · United States · https://www.mckesson.com